SN1991bg-like supernovae are a compelling source of most Galactic antimatter

The Milky Way Galaxy glows with the soft gamma ray emission resulting from the annihilation of $\sim 5 \times 10^{43}$ electron-positron pairs every second. The origin of this vast quantity of antimatter and the peculiar morphology of the 511keV gamma ray line resulting from this annihilation have been the subject of debate for almost half a century. Most obvious positron sources are associated with star forming regions and cannot explain the rate of positron annihilation in the Galactic bulge, which last saw star formation some $10\,\mathrm{Gyr}$ ago, or else violate stringent constraints on the positron injection energy. Radioactive decay of elements formed in core collapse supernovae (CCSNe) and normal Type Ia supernovae (SNe Ia) could supply positrons matching the injection energy constraints but the distribution of such potential sources does not replicate the required morphology. We show that a single class of peculiar thermonuclear supernova - SN1991bg-like supernovae (SNe 91bg) - can supply the number and distribution of positrons we see annihilating in the Galaxy through the decay of $^{44}$Ti synthesised in these events. Such $^{44}$Ti production simultaneously addresses the observed abundance of $^{44}$Ca, the $^{44}$Ti decay product, in solar system material.Comment: Accepted for publication in Proceedings of IAU Symposium 322: The Multimessenger Astrophysics of the Galactic Center 4 page

Constraints on positron annihilation kinematics in the inner Galaxy

Context. The annihilation of cosmic positrons with electrons in the interstellar medium results in the strongest persistent γ-ray line signal in the sky. For the past 50 yr, this 511 keV emission - predominantly from the galactic bulge region and from a low surface-brightness disk - has puzzled observers and theoreticians. A key issue for understanding positron astrophysics is found in cosmic-ray propagation, especially at low kinetic energies (≲ 10 MeV). Aims. We want to shed light on how positrons propagate and the resulting morphology of the annihilation emission. We approach this "positron puzzle" by inferring kinematic information of the 511 keV line in the inner radian of the Galaxy. This constrains propagation scenarios and positron source populations in the Milky Way. Methods. By dissecting the positron annihilation emission as measured with INTEGRAL/SPI, we derived spectra for individual and independent regions in the sky. The centroid energies of these spectra around the 511 keV line are converted into Doppler shifts, representing the line-of-sight velocity along different galactic longitudes. This results in a longitude-velocity diagram of positron annihilation. From high-resolution spectra, we also determined Doppler-broadening from γ-ray line shape parameters to study annihilation conditions as they vary with galactic longitude. Results. We found line-of-sight velocities in the 511 keV line that are consistent with zero, as well as with galactic rotation from CO measurements (2-3 km s -1 deg -1), and measurements of radioactive 26Al (7.5-9.5 km s -1 deg -1). The velocity gradient in the inner ±30° is determined to be 4 ± 6 km s -1 deg -1. The width of the 511 keV line is constant as a function of longitude at 2.43 ± 0.14 keV, with possibly different values towards the disk. The positronium fraction is found to be 1.0 along the galactic plane. Conclusions. The weak signals in the disk leave the question open of whether positron annihilation is associated with the high velocities seen in 26Al or rather with ordinarily rotating components of the Milky Way's interstellar medium. We confirm previous results that positrons are slowed down to the 10 eV energy scale before annihilation and constrain bulk Doppler-broadening contributions to ≲ 1.25 keV in the inner radian. Consequently, the true annihilation conditions remain unclear.Peer reviewedFinal Accepted Versio

SN1991bg-like supernovae are associated with old stellar populations

SN1991bg-like supernovae are a distinct subclass of thermonuclear supernovae (SNe Ia). Their spectral and photometric peculiarities indicate their progenitors and explosion mechanism differ from `normal' SNe Ia. One method of determining information about supernova progenitors we cannot directly observe is to observe the stellar population adjacent to the apparent supernova explosion site to infer the distribution of stellar population ages and metallicities. We obtain integral field observations and analyse the spectra extracted from regions of projected radius $\sim\,\mathrm{kpc}$ about the apparent SN explosion site for 11 91bg-like SNe in both early- and late-type galaxies. We utilize full-spectrum spectral fitting to determine the ages and metallicities of the stellar population within the aperture. We find that the majority of the stellar populations that hosted 91bg-like supernovae have little recent star formation. The ages of the stellar populations suggest that that 91bg-like SN progenitors explode after delay times of $>6\,\mathrm{Gyr}$, much longer than the typical delay time of normal SNe Ia, which peaks at $\sim 1\,\mathrm{Gyr}$.Comment: 12 pages, 3 figures, 3 tables, submitted to Publications of the Astronomical Society of Australi

Prospects of direct detection of 48^{48}V gamma-rays from thermonuclear supernovae

Detection of gamma-rays emitted by radioactive isotopes synthesized in stellar explosions can give important insights into the processes that power transients such as supernovae, as well as providing a detailed census of the abundance of different isotope species relevant to the chemical evolution of the Universe. Observations of nearby supernovae have yielded observational proof that $^{57}$Co powered the late-time evolution of SN1987A's lightcurve, and conclusive evidence that $^{56}$Ni and its daughter nuclei power the light curves of Type Ia supernovae. In this paper we describe the prospects for detecting nuclear decay lines associated with the decay of $^{48}$V, the daughter nucleus of $^{48}$Cr, which is expected to be synthesised in large quantities - $M_{\mathrm{Cr}}\sim1.9\times10^{-2}\,\mathrm{M_\odot}$ - in transients initiated by explosive helium burning ($\alpha$-capture) of a thick helium shell. We calculate emergent gamma-ray line fluxes for a simulated explosion model of a thermonuclear explosion of carbon-oxygen white dwarf core of mass $0.45\,M_{\odot}$ surrounded by a thick helium layer of mass $0.21\,M_{\odot}$. We present observational limits on the presence of $^{48}$V in nearby SNe Ia 2014J using the \textit{INTEGRAL} space telescope, excluding a $^{48}$Cr production on the surface of more than $0.1\,\mathrm{M_{\odot}}$. We find that the future gamma-ray mission AMEGO will have an approximately 5 per cent chance of observing $^{48}$V gamma-rays from such events during the currently-planned operational lifetime, based on our birthrate predictions of faint thermonuclear transients. We describe the conditions for a $3\sigma$ detection by the gamma-ray telescopes \textit{INTEGRAL}/SPI, COSI and AMEGO.Comment: 9 pages, 3 figures, submitted to MNRAS, minor revisions Sept 202

Diffuse Galactic antimatter from faint thermonuclear supernovae in old stellar populations

Our Galaxy hosts the annihilation of a few $\times 10^{43}$ low-energy positrons every second. Radioactive isotopes capable of supplying such positrons are synthesised in stars, stellar remnants, and supernovae. For decades, however, there has been no positive identification of a main stellar positron source leading to suggestions that many positrons originate from exotic sources like the Galaxy's central super-massive black hole or dark matter annihilation. %, but such sources would not explain the recently-detected positron signal from the extended Galactic disk. Here we show that a single type of transient source, deriving from stellar populations of age 3-6 Gyr and yielding ~0.03 $M_\odot$ of the positron emitter $^{44}$Ti, can simultaneously explain the strength and morphology of the Galactic positron annihilation signal and the solar system abundance of the $^{44}$Ti decay product $^{44}$Ca. This transient is likely the merger of two low-mass white dwarfs, observed in external galaxies as the sub-luminous, thermonuclear supernova known as SN1991bg-like.Comment: 28 pages main text with 4 figures in preprint style; 26 pages of Supplementary Informatio

SERDP ER-1376 Enhancement of In Situ Bioremediation of Energetic Compounds by Coupled Abiotic/Biotic Processes:Final Report for 2004 - 2006

This project was initiated by SERDP to quantify processes and determine the effectiveness of abiotic/biotic mineralization of energetics (RDX, HMX, TNT) in aquifer sediments by combinations of biostimulation (carbon, trace nutrient additions) and chemical reduction of sediment to create a reducing environment. Initially it was hypothesized that a balance of chemical reduction of sediment and biostimulation would increase the RDX, HMX, and TNT mineralization rate significantly (by a combination of abiotic and biotic processes) so that this abiotic/biotic treatment may be a more efficient for remediation than biotic treatment alone in some cases. Because both abiotic and biotic processes are involved in energetic mineralization in sediments, it was further hypothesized that consideration for both abiotic reduction and microbial growth was need to optimize the sediment system for the most rapid mineralization rate. Results show that there are separate optimal abiotic/biostimulation aquifer sediment treatments for RDX/HMX and for TNT. Optimal sediment treatment for RDX and HMX (which have chemical similarities and similar degradation pathways) is mainly chemical reduction of sediment, which increased the RDX/HMX mineralization rate 100 to150 times (relative to untreated sediment), with additional carbon or trace nutrient addition, which increased the RDX/HMX mineralization rate an additional 3 to 4 times. In contrast, the optimal aquifer sediment treatment for TNT involves mainly biostimulation (glucose addition), which stimulates a TNT/glucose cometabolic degradation pathway (6.8 times more rapid than untreated sediment), degrading TNT to amino-intermediates that irreversibly sorb (i.e., end product is not CO2). The TNT mass migration risk is minimized by these transformation reactions, as the triaminotoluene and 2,4- and 2,6-diaminonitrotoluene products that irreversibly sorb are no longer mobile in the subsurface environment. These transformation rates are increased 13 times further by chemical reduction of sediment. Dithionite reduction alone is not an effective treatment for TNT (intermediates that irreversibly sorb are not produced), even though the TNT degradation rate (to 2- or 4-aminodinitrotoluene) increases

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.

BACKGROUND: A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis of four trials. METHODS: This analysis includes data from four ongoing blinded, randomised, controlled trials done across the UK, Brazil, and South Africa. Participants aged 18 years and older were randomly assigned (1:1) to ChAdOx1 nCoV-19 vaccine or control (meningococcal group A, C, W, and Y conjugate vaccine or saline). Participants in the ChAdOx1 nCoV-19 group received two doses containing 5 × 1010 viral particles (standard dose; SD/SD cohort); a subset in the UK trial received a half dose as their first dose (low dose) and a standard dose as their second dose (LD/SD cohort). The primary efficacy analysis included symptomatic COVID-19 in seronegative participants with a nucleic acid amplification test-positive swab more than 14 days after a second dose of vaccine. Participants were analysed according to treatment received, with data cutoff on Nov 4, 2020. Vaccine efficacy was calculated as 1 - relative risk derived from a robust Poisson regression model adjusted for age. Studies are registered at ISRCTN89951424 and ClinicalTrials.gov, NCT04324606, NCT04400838, and NCT04444674. FINDINGS: Between April 23 and Nov 4, 2020, 23 848 participants were enrolled and 11 636 participants (7548 in the UK, 4088 in Brazil) were included in the interim primary efficacy analysis. In participants who received two standard doses, vaccine efficacy was 62·1% (95% CI 41·0-75·7; 27 [0·6%] of 4440 in the ChAdOx1 nCoV-19 group vs71 [1·6%] of 4455 in the control group) and in participants who received a low dose followed by a standard dose, efficacy was 90·0% (67·4-97·0; three [0·2%] of 1367 vs 30 [2·2%] of 1374; pinteraction=0·010). Overall vaccine efficacy across both groups was 70·4% (95·8% CI 54·8-80·6; 30 [0·5%] of 5807 vs 101 [1·7%] of 5829). From 21 days after the first dose, there were ten cases hospitalised for COVID-19, all in the control arm; two were classified as severe COVID-19, including one death. There were 74 341 person-months of safety follow-up (median 3·4 months, IQR 1·3-4·8): 175 severe adverse events occurred in 168 participants, 84 events in the ChAdOx1 nCoV-19 group and 91 in the control group. Three events were classified as possibly related to a vaccine: one in the ChAdOx1 nCoV-19 group, one in the control group, and one in a participant who remains masked to group allocation. INTERPRETATION: ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials. FUNDING: UK Research and Innovation, National Institutes for Health Research (NIHR), Coalition for Epidemic Preparedness Innovations, Bill & Melinda Gates Foundation, Lemann Foundation, Rede D'Or, Brava and Telles Foundation, NIHR Oxford Biomedical Research Centre, Thames Valley and South Midland's NIHR Clinical Research Network, and AstraZeneca

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Background A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis of four trials. Methods This analysis includes data from four ongoing blinded, randomised, controlled trials done across the UK, Brazil, and South Africa. Participants aged 18 years and older were randomly assigned (1:1) to ChAdOx1 nCoV-19 vaccine or control (meningococcal group A, C, W, and Y conjugate vaccine or saline). Participants in the ChAdOx1 nCoV-19 group received two doses containing 5 × 1010 viral particles (standard dose; SD/SD cohort); a subset in the UK trial received a half dose as their first dose (low dose) and a standard dose as their second dose (LD/SD cohort). The primary efficacy analysis included symptomatic COVID-19 in seronegative participants with a nucleic acid amplification test-positive swab more than 14 days after a second dose of vaccine. Participants were analysed according to treatment received, with data cutoff on Nov 4, 2020. Vaccine efficacy was calculated as 1 - relative risk derived from a robust Poisson regression model adjusted for age. Studies are registered at ISRCTN89951424 and ClinicalTrials.gov, NCT04324606, NCT04400838, and NCT04444674. Findings Between April 23 and Nov 4, 2020, 23 848 participants were enrolled and 11 636 participants (7548 in the UK, 4088 in Brazil) were included in the interim primary efficacy analysis. In participants who received two standard doses, vaccine efficacy was 62·1% (95% CI 41·0–75·7; 27 [0·6%] of 4440 in the ChAdOx1 nCoV-19 group vs71 [1·6%] of 4455 in the control group) and in participants who received a low dose followed by a standard dose, efficacy was 90·0% (67·4–97·0; three [0·2%] of 1367 vs 30 [2·2%] of 1374; pinteraction=0·010). Overall vaccine efficacy across both groups was 70·4% (95·8% CI 54·8–80·6; 30 [0·5%] of 5807 vs 101 [1·7%] of 5829). From 21 days after the first dose, there were ten cases hospitalised for COVID-19, all in the control arm; two were classified as severe COVID-19, including one death. There were 74 341 person-months of safety follow-up (median 3·4 months, IQR 1·3–4·8): 175 severe adverse events occurred in 168 participants, 84 events in the ChAdOx1 nCoV-19 group and 91 in the control group. Three events were classified as possibly related to a vaccine: one in the ChAdOx1 nCoV-19 group, one in the control group, and one in a participant who remains masked to group allocation. Interpretation ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials